PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
195 hedge funds and large institutions have $421M invested in PDL BioPharma, Inc. in 2016 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 74 increasing their positions, 61 reducing their positions, and 32 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 61
4% less funds holding
Funds holding: 204 → 195 (-9)
12% less capital invested
Capital invested by funds: $479M → $421M (-$58.5M)
19% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 32
45% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $2.76M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$7.42M |
| 2 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$7.05M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.94M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.45M |
| 5 |
QI
QS Investors
New York
|
+$3.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$20.3M |
| 2 |
GXMC
Global X Management Company
New York
|
-$7.85M |
| 3 |
Goldman Sachs
New York
|
-$4.99M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$4.07M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$3.54M |
PDLI Hedge Fund Activity: Q1 2016 in Review
195 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2016, worth a combined $421M — down 12% from $479M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of PDLI and 26 opened new positions — a net loss of 6 holders — while 61 trimmed existing stakes and 74 added.
The largest buyer was Renaissance Technologies, adding an estimated $7.42M. The largest seller was BlackRock Fund Advisors, cutting an estimated $20.3M.
- 195 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2016, down from 204 in Q4 2015.
- Funds reported $421M of PDL BioPharma, Inc. stock for Q1 2016, down 12% quarter-over-quarter.
- 26 funds opened new PDL BioPharma, Inc. positions in Q1 2016 and 32 closed out, a net change of -6 holders.
- The largest PDL BioPharma, Inc. buyer in Q1 2016 was Renaissance Technologies, an estimated $7.42M added.
- The largest PDL BioPharma, Inc. seller in Q1 2016 was BlackRock Fund Advisors, an estimated $20.3M sold.
Based on aggregated 13F filings for Q1 2016.